Docs not fans of Valeant-Allergan mix

Share this article:

The Allergan-Valeant fight is already changing how doctors think about their prescription habits.

The Wall Street Journal reports that 44% of dermatologists and plastic surgeons polled in a Sanford Bernstein survey said they would consider Botox alternatives if Allergan becomes a Valeant subsidiary.

Bernstein analyst Ronnie Gal created the survey and notes that the answers are all well and good, but doctors have few alternatives.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.